Table 2 Linear regression analysis of treatment assignment and baseline BAMA HCoV antibody response magnitude as predictors of SARS-CoV-2 GCN-4 ELISA binding antibody concentration at D36 among 18–49 yr-old participants receiving a two-dose regimen (N = 173)

From: Prior human endemic coronavirus exposure does not affect humoral responses to SARS-CoV-2 protein vaccines

 

Coefficient

SE

P value

(Intercept)

−0.96

0.87

0.27

Low dose + AF03 (two doses schedule)

2.31

0.16

<0.001

Low dose + AS03 (two doses schedule)

2.67

0.13

<0.001

High dose + AF03 (two doses schedule)

2.71

0.16

<0.001

High dose + AS03 (two doses schedule)

2.95

0.13

<0.001

High dose (two doses schedule)

0.43

0.16

0.01

HCoV 229E spike

−0.04

0.19

0.84

HCoV 229E RBD

0.24

0.21

0.26

HCoV HKU1 spike

0.25

0.23

0.28

HCoV HKU1 RBD

−0.10

0.16

0.53

HCoV NL63 spike

0.01

0.24

0.98

HCoV NL63 RBD

−0.04

0.29

0.88

HCoV OC43 spike

−0.12

0.27

0.65

HCoV OC43 RBD

0.08

0.16

0.63

  1. BAMA Binding Antibody Multiplex Assay, HCoV human coronavirus, RBD receptor binding domain, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, SE standard error, yr year
Back to article page